Disorders of Blood Coagulation Flashcards

1
Q

What is haemostasis?

A

life preserving process designed to maintain blood flow:

  • respond to tissue injury
  • curtail blood loss
  • restore vascular integrity & promote healing
  • limit infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Effect of infection on haemostasis

A

Infection is an important initiator of haemostasis. Coagulation therefore not only stops blood loss, but can act as a mechanism against infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Meningococcal septicaemia

A

Bacterial infection initiates haemostasis, forming excessive clots which occlude blood vessels and specific areas lose their blood supply, resulting in disseminated intravascular coagulation (DIC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Key components of haemostasis

A

Endothelium
Coagulation
Platelets
Fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a blood clot made of?

A
  • fibrin mesh (end point of coagulation)
  • platelets
  • red blood cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Phases of the Haemostatic system

A

1) Primary haemostasis
2) Secondary haemostasis
3) Fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Primary haemostasis

A

Formation of platelet plug:

  • Vasoconstriction (immediate)
  • Platelet adhesion (within seconds)
  • Platelet aggregation & contraction (within minutes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Steps of primary haemostasis

A

1) The endothelium continuously releases small amounts of vWf which circulates in the blood.
2) Endothelial cells also store vWF in Weibel-Palade bodies for release when approximately stimulated
3) If collagen becomes exposed to blood (through damage), vWF binds to it.
4) Platelets express receptors for both collagen and vWF and become activated when these proteins bind to them
5) Activated platelets express functional fibrinogen receptors, which are required for aggreagation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where does vWF reside?

When is vWF released and unravelled?

A

lies in the endothelium

when there is increased stress during blood vessel injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

why are blood clots localised?

A

To prevent systemic blood clots

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Function of vWF

A

attaches to collagen in the subendothelium and acts as an anchor for platelets to attach to it and form a platelet plug (platelet aggregation)
-this prevents excessive blood loss at site of injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Secondary haemostasis

A

Formation of the fibrin clot:

  • activation of coagulation factors (within seconds)
  • formation of fibrin (within minutes)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Steps of Secondary haemostasis

A

1) Tissue factor, expressed by nearly all sub-endothelial cells activates the coagulation cascade to which initiates a minor burst of thrombin
2) Factor FVIIa binds to TF, which leads to the conversion of prothrombin to thrombin.
3) Thrombin activates receptors on platelets as well as the endothelium, amplifying platelet aggregation and initiating release of stored vVF from endothelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Steps of the amplification stage

A

1) Thrombin activates two cofactors: Factor VIIIa and Factor Va which form calcium-ion dependent complexes on the surface of platelets with Factor IXa (tenase complex) and Factor Xa (the prothrombinase complex).
2) These complexes greatly accelerate the production of Factor Xa and thrombin, respectively.
3) The greatly increased production of thrombin via tenase and prothrombinase contributes considerably more to the process. Thrombin will convert fibrinogen to the fibrin mesh.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How many clotting factors are there?

Where are the majority of clotting factors produced?

A

13 clotting factors

liver
-hence people with liver disease sometimes have bleeding disorders due to deficiencies in clotting factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Coagulation pathways

A

1 - extrinsic pathway
2 - intrinsic pathway
3 - common pathway (convergence of 1 and 2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Intrinsic pathway of coagulation

Extrinsic pathway of coagulation

A

Pathway involving surface contact

Factors released by damaged tissues begin cascade (e.g. tissue factor)
-primary way in which we form a clot

18
Q

What does each reaction in the coagulation pathways (intrinsic and extrinsic) require?

A

Ca2+
Phospholipid
+/- Specific co-factors

19
Q

FVII deficiency

FXII deficiency

A

causes bleeding

not associated with bleeding

20
Q

What initiates coagulation?

A

when sub-endothelial tissue is exposed to the circulation at the site of injury

21
Q

Fibrinolysis

A

dissolution of a clot
-clot limiting mechanism

> activation of fibrinolysis (minutes)
lysis of the plug (within hours)

22
Q

Key substances in fibrinolysis

A
  • plasminogen
  • tissue plasminogen activator (t-PA) & urokinase plasminogen activator
  • ⍺2-plasmin inhibitor
23
Q

What is plasminogen?

Function of plasmin

How is plasminogen converted to plasmin?

A

precursor to the active enzyme plasmin

breaks down fibrin clots

tPA converts plasminogen to plasmin

24
Q

D dimers

Fibrin Degradation Products (FDPs)

A

products generated when cross-linked fibrin is degraded
*D dimer levels used clinically to detect for clots

products generated when non-cross linked fibrin or fibrinogen is broken down

25
Q

Therapeutic thrombolysis for myocardial infarction

A

tPA and streptokinase (bacterial activator)

26
Q

The process of fibrinolysis

A
  • Plasminogen is converted to plasmin by tissue plasminogen activator (t-PA).
  • Plasmin degrades the fibrin mesh to fibrin degradation products which can be cleared.
27
Q

Thrombosis vs Bleeding

A

There needs to be a state of equilibrium between factors which break down clots (fibrinolytic factors, anticoagulant proteins) and factors which promote clotting (coagulation factors, platelets) to maintain normal haemostasis

28
Q

Cause of thrombosis

A
  • High coagulation factors and platelets

- Low fibrinolytic factors and anticoagulant proteins

29
Q

Consequence of thrombosis

A

Chronic venous insufficiency:

  • atrophic changes
  • hyperpigmentation
  • ulceration
  • infection
30
Q

Cause of bleeding

Consequence of bleeding

A
  • High fibrinolytic factors and anticoagulant proteins
  • Low coagulation factors and platelets

Easy bruising (ecchymosis)

31
Q

Natural anticoagulants (I)

A
Antithrombin (AT) is a serpin
(serine protease inhibitor)
Activity greatly enhanced by 
binding heparan binding sites on 
endothelial cells
Major checkpoint to inhibit 
coagulation (thrombin), IXa, Xa)
Its heparan binding domain is the 
basis of the anticoagulant activity 
of heparin which increases the 
activity of ATIII
Protein C and protein S are natural 
anticoagulant plasma proteins
Protein C is activated by thrombin 
bound to thrombomodulin (TM) 
on endothelial cells to form 
activated protein C (APC)
Protein S is an APC cofactor which 
helps binding to cell surfaces
APC degrades cofactors FVa and 
FVIIIa
32
Q

Haemophilia - failure to clot leading to haemorrhage

A
  • Mutations in coagulation factors (haemophilia A and B)
  • Platelet disorders (von Willebrand disease)
  • Collagen abnormalities (fragile blood vessels and bruising)

Haemophilia A (80%)
Mutated FVIII
Haemophilia B (20%)
Mutated FIX

33
Q

Thrombophilia – excessive clotting leading to thrombosis

A
  • Inherited: mutations in coagulation factors (DVT)

* Acquired: malignancy increases clotting factors (DVT)

34
Q

Disseminated intravascular coagulation (DIC) – whole body clots

A
  • Infection
  • Depletion of clotting factors and platelets leads to bleeding

As in sepsis (body’s response to an infection injures its own tissues and organs)
Depletion of clotting factors and platelets leads to bleeding

35
Q

Excessive clotting

A

Factor V Leiden mutation
Resistance to APC
FVa is not inactivated

Antithrombin deficiency
Thrombin, IXa and FXa are not inactivated

Protein C deficiency
Protein S deficiency
Increases risk of DVT

36
Q

Prothrombin Time (PT)

A

test to measure activity of prothrombin in the blood:

  • sensitive to extrinsic pathway and to a lesser extent common pathway
  • tissue factor driven
37
Q

Activated Partial Thromboplastin Time (APTT)

A
  • sensitive to intrinsic pathway and to a lesser extent common pathway
  • contact activated

*normal= 30-45 seconds

38
Q

Thrombin Time (TT)

A

Determines if adequate fibrinogen is present for normal coagulation:
-sensitive to defects in conversion of fibrinogen to fibrin

39
Q

Haemophilia

von Willebrand disease

A

Bleeding into joints

Affects mucous membranes.
Mostly mild, but bleeding can vary in severity
Inherited defect/deficiency in vWF

40
Q

Virchow’s Triad

A

Development of a venous thrombus depends on:
• Alterations in the constituents of the blood
• Changes in normal blood flow
• Damage to the endothelial layer

41
Q

Management of VTE

A
Investigations pre-treatment
• Clotting screen
– Prothrombin time 
– Partial thromboplastin 
time
– Thrombin time
• Full blood count
• Renal screen
• Liver function tests
– If clinical suspicion of 
liver disease
Treatment
• DVT: Anticoagulate
• Immediate anticoagulant effect
• Heparin or warfarin
• DOACs
– Rivaroxaban, apixaban (FXa inhibitors)
– Dabigatran (thrombin (FIIa) inhibitor)
• PE: Thrombolysis
• Alteplase (tissue plasminogen activator)
• Streptokinase 
• Followed by anticoagulant to prevent recurrence
42
Q

Deep Vein Thrombosis clinical features

A
• Pain & tenderness of veins
• Limb swelling 
• Superficial venous distension
• Increased skin temperature 
• Skin discoloration
All reflect obstruction to the venous drainage
Increased risk of pulmonary embolism